Sign In
Section Navigation
Common TitlePACTG P1005
Official Title A Phase I/II Study of T-20, a Fusion Inhibitor, in HIV-1 Infected Children
Phase Phase I
ClinicalTrials.gov NCT00001118
Treatments
Enfuvirtide
Enfuvirtide Fuzeon

Enfuvirtide

Tradename:FuzeonOther Names:T-20Class:Entry Inhibitors
Categories Resistance/Virological FailurePediatricsTreatment-Experienced
Funding
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
  • Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2002;21:653-9.
    [PubMed Abstract]
  • Church JA, Hughes M, Chen J, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J. 2004;23:713-8.
    [PubMed Abstract]
  • Soy D, Aweeka FT, Church JA, et al. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther. 2003;74:569-80.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.